Conduit Pharmaceuticals Statistics
Share Statistics
Conduit Pharmaceuticals has 119.86M shares outstanding. The number of shares has increased by 62.35% in one year.
| Shares Outstanding | 119.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 24.85% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 72.97M |
| Failed to Deliver (FTD) Shares | 917.18K |
| FTD / Avg. Volume | 3.36% |
Short Selling Information
The latest short interest is 3.57M, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 3.57M |
| Short % of Shares Out | 2.98% |
| Short % of Float | 4.89% |
| Short Ratio (days to cover) | 0.14 |
Valuation Ratios
The PE ratio is -569.59 and the forward PE ratio is null.
| PE Ratio | -569.59 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -666.81 |
| P/FCF Ratio | -39.45 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Conduit Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of -2.16.
| Current Ratio | 3.18 |
| Quick Ratio | 3.18 |
| Debt / Equity | -2.16 |
| Total Debt / Capitalization | 186.55 |
| Cash Flow / Debt | -7.84 |
| Interest Coverage | -26.36 |
Financial Efficiency
Return on equity (ROE) is 1.17% and return on capital (ROIC) is -722.83%.
| Return on Equity (ROE) | 1.17% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -722.83% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -76.43K |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -167.90K |
| Effective Tax Rate | 0.31 |
Stock Price Statistics
The stock price has increased by -98.65% in the last 52 weeks. The beta is 2.12, so Conduit Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 2.12 |
| 52-Week Price Change | -98.65% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 47.77 |
| Average Volume (20 Days) | 27.27M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -5.56M |
| Net Income | -535.00K |
| EBITDA | -324.00K |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 4.23M in cash and 985.00K in debt, giving a net cash position of 3.24M.
| Cash & Cash Equivalents | 4.23M |
| Total Debt | 985.00K |
| Net Cash | 3.24M |
| Retained Earnings | -11.30M |
| Total Assets | 2.99M |
| Working Capital | -10.58M |
Cash Flow
In the last 12 months, operating cash flow was -7.72M and capital expenditures 0, giving a free cash flow of -7.72M.
| Operating Cash Flow | -7.72M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.72M |
| FCF Per Share | -0.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CDT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -128.57% |
| FCF Yield | -88.53% |
Analyst Forecast
Currently there are no analyst rating for CDT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 402.87 |
| Piotroski F-Score | 3 |